MX2024009559A - Métodos de tratamiento mediante el uso de moduladores del canal de calcio tipo t. - Google Patents

Métodos de tratamiento mediante el uso de moduladores del canal de calcio tipo t.

Info

Publication number
MX2024009559A
MX2024009559A MX2024009559A MX2024009559A MX2024009559A MX 2024009559 A MX2024009559 A MX 2024009559A MX 2024009559 A MX2024009559 A MX 2024009559A MX 2024009559 A MX2024009559 A MX 2024009559A MX 2024009559 A MX2024009559 A MX 2024009559A
Authority
MX
Mexico
Prior art keywords
calcium channel
type calcium
methods
treatment
channel modulators
Prior art date
Application number
MX2024009559A
Other languages
English (en)
Spanish (es)
Inventor
Bernard Ravina
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of MX2024009559A publication Critical patent/MX2024009559A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024009559A 2022-02-03 2023-02-03 Métodos de tratamiento mediante el uso de moduladores del canal de calcio tipo t. MX2024009559A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263306340P 2022-02-03 2022-02-03
PCT/US2023/061973 WO2023150703A2 (en) 2022-02-03 2023-02-03 Methods of treatment using t-type calcium channel modulators

Publications (1)

Publication Number Publication Date
MX2024009559A true MX2024009559A (es) 2024-09-23

Family

ID=87552982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009559A MX2024009559A (es) 2022-02-03 2023-02-03 Métodos de tratamiento mediante el uso de moduladores del canal de calcio tipo t.

Country Status (10)

Country Link
US (1) US20250170114A1 (enExample)
EP (1) EP4472633A4 (enExample)
JP (1) JP2025505578A (enExample)
KR (1) KR20240144291A (enExample)
CN (1) CN118785905A (enExample)
AU (1) AU2023216271A1 (enExample)
CA (1) CA3243616A1 (enExample)
IL (1) IL314576A (enExample)
MX (1) MX2024009559A (enExample)
WO (1) WO2023150703A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101212974A (zh) * 2005-06-29 2008-07-02 默克公司 4-氟-哌啶t-型钙通道拮抗剂
JP6790094B2 (ja) * 2015-11-12 2020-11-25 エーエフエーエスシーアイ,インコーポレイテッド イオンチャネル阻害化合物、医薬製剤および使用
US11744825B2 (en) * 2018-08-28 2023-09-05 Afasci, Inc. Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds
EP3996746A4 (en) * 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
EP4142764A4 (en) * 2020-04-29 2024-05-29 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators
WO2022099207A1 (en) * 2020-11-09 2022-05-12 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
CN119584962A (zh) * 2022-05-09 2025-03-07 普拉西斯精密医药公司 T型钙通道调节剂的使用方法

Also Published As

Publication number Publication date
WO2023150703A3 (en) 2023-09-14
EP4472633A4 (en) 2026-01-14
WO2023150703A2 (en) 2023-08-10
US20250170114A1 (en) 2025-05-29
EP4472633A2 (en) 2024-12-11
CN118785905A (zh) 2024-10-15
JP2025505578A (ja) 2025-02-28
IL314576A (en) 2024-09-01
KR20240144291A (ko) 2024-10-02
AU2023216271A1 (en) 2024-08-15
CA3243616A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
ZA202109010B (en) Compounds and methods for the treatment of covid-19
NZ800220A (en) Methods of treating heart failure by administering omecamtiv mecarbil
PH12022552702A1 (en) Methods of treating diabetic kidney disease
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2022011041A (es) Tratamiento de dolor y vasoconstriccion.
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
MX2022011490A (es) Tratamiento o metodo de prevencion de falla cardiaca cronica.
PH12023550780A1 (en) Line-1 inhibitors to treat disease
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2023150703A3 (en) Methods of treatment using t-type calcium channel modulators
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
MX2024000081A (es) Derivados de cannabicromeno y métodos para fabricar y usar los mismos.
WO2022221349A3 (en) Methods and compositions for treating long covid-19
WO2025058667A3 (en) Prevention and treatment of conditions using ethyl pyruvate
MX2025013588A (es) Tratamiento a largo plazo contra la pérdida de cabello
MX2024015824A (es) Metodos para el tratamiento o la prevencion del sindrome de vejiga hiperactiva
MX2024002602A (es) Métodos para prevenir y tratar el dolor y síntomas asociados.
MX2023013065A (es) Moduladores de canales de potasio de gran conductancia, composiciones de estos, métodos para su fabricación y métodos para su uso.